Outlook Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview

Outlook Therapeutics

12/05/2025 14:58

Outlook Therapeutics Inc OTLK.OQ OTLK.O is expected to show a rise in quarterly revenue when it reports  results on May 14 (estimated) for the period ending March 31 2025

The Iselin New Jersey-based  company is expected to report revenue of $702.6 thousand, according to the mean estimate from 5 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Outlook Therapeutics Inc is for a loss of 60 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Outlook Therapeutics Inc is $9.50‚Äč, above‚Äč its last closing price of $1.53. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.69
-0.77
0.72
Beat
192.9
Sep. 30 2024
-0.86
-0.83
0.76
Beat
191.1
Jun. 30 2024
-1.02
-1.00
-0.83
Beat
16.8‚Äč
Mar. 31 2024
-0.96
-0.85
-1.55
Missed
-82.4
‚Äč‚ÄčDec. 31 2023
-0.92
-1.00
-0.80
Beat
20
Sep. 30 2023
-1.16
-1.17
-1.00
Beat
14.9‚Äč
Jun. 30 2023
-0.82
-1.03
-1.60
Missed
-55.6
Mar. 31 2023
-1.19
-1.30
-0.60
Beat
53.8

This summary was machine generated May 12 at 13:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)